Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule …
| Métrica | FAGR.BR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 62.4% | 57.4% | +5.0% |
| Operating Margin | 15.0% | -34.4% | +49.4% |
| Net Margin | 9.2% | -32.5% | +41.7% |
| FCF Margin | 9.6% | -12.6% | +22.2% |
| ROE | 16.1% | -39.2% | +55.2% |
| ROA | 7.4% | -30.9% | +38.4% |
| Current Ratio | 1.86 | 2.73 | -0.87 |
| Debt / Equity | 0.68 | 0.28 | +0.40 |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 7.4% | — |
| ✓Flujo de caja operativo positivo | €110M | €125M |
| ✓Rentabilidad sobre activos al alza | 7.4% | 7.0% |
| ✓Caja operativa/activos supera al ROA | 10.1% | ROA 7.4% |
| ✓Menos deuda a largo plazo | 31.5% | 32.3% |
| ✗Mejor liquidez (ratio corriente) | 1.86 | 1.92 |
| ✗Sin aumentar el nº de acciones | 73M | 73M |
| ✓Margen bruto al alza | 62.3% | 60.5% |
| ✓Rotación de activos al alza | 0.80 | 0.76 |
| Calidad del negocio | FY24 |
|---|---|
| ✗Margen FCF > 10 % | 9.6% |
| ✓ROCE > 10 % | 14.7% |
| ✓Ventas > 5 %/año (3 años) | 15.0% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 3.0% |
FAGRON cotiza a 23.50 EUR y tiene una capitalización bursátil de €1.7B. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud